Radar: one dot per trial, by target and phase. Pipeline: one row per molecule, from phase 1 to approval.
Theranostic Atlas · updated every week
Radioligand therapy and molecular imaging: every ongoing trial and every approved product, arranged by target and phase on two interactive radars, from the public registries ClinicalTrials.gov and CTIS.
A LaRadiopharmacie.fr project · automatic update every Monday.
Targeted radionuclide therapy (radioligand therapy): clinical trials and approved products, arranged by target (sectors). Rings run from approved products at the centre to phase 1 at the edge; each dot is a trial (or a molecule), coloured by radionuclide. Click a sector, a ring, a dot or a diamond.
Monthly updates
Published articles (PubMed) reporting the results of prospective trials, summarised from their abstract. "Positive" and "negative" refer to the primary endpoint; "early" means a phase 1 trial whose objective is safety. The radionuclide, emission and search filters also apply here.
Diagnostic PET and SPECT tracers: clinical trials and approved products, arranged by target or mechanism (sectors) and grouped by clinical domain (coloured band). Rings run from approved tracers at the centre to phase 1, then to studies without a phase (clinical use, comparisons, phase 4) at the edge. Each dot is a trial (or a tracer), coloured by radionuclide.
Monthly updates
Published articles (PubMed) reporting the results of prospective trials, summarised from their abstract. "Positive" and "negative" refer to the primary endpoint; "early" means a phase 1 trial whose objective is safety. The modality, radionuclide and search filters also apply here.